Xia Feng, Huang Zhiyuan, Zhang Qiao, Ndhlovu Elijah, Zhang Mingyu, Chen Xiaoping, Zhang Bixiang, Zhu Peng
Department of Hepatic Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Guangdong Medical University, Zhanjiang, China.
Front Oncol. 2022 May 17;12:865696. doi: 10.3389/fonc.2022.865696. eCollection 2022.
Ruptured hepatocellular carcinoma (rHCC) is classified as T4 according to the TNM staging system with a very poor (does not achieve expected) prognosis, which has always been controversial. This study aimed at assessing the specific impact of different tumor diameters on the posttreatment prognosis of BCLC stage 0/A rHCC patients.
Data from 258 patients with BCLC stage 0/A HCC treated in our center from January 2008 to December 2017 were collected, including 143 rHCC patients and 115 patients with non-ruptured HCC (nrHCC). With the help of X-tile software, we determined the cutoff value of the tumor diameter in patients with rHCC. Using 8 cm as the cutoff, we divided rHCC patients into Small-rHCC (n = 96) and Large-rHCC (n = 47) groups, compared the prognoses of the S-rHCC and L-rHCC groups, as well as the prognoses of the two groups with the nrHCC group using the Kaplan-Meier method, and screened the prognostic factors of rHCC patients using the multivariate Cox risk model.
The OS of the S-rHCC group was significantly higher than that of the L-rHCC group [HR = 2.41 (1.60-3.63)], and the OS of the nrHCC group was comparable to that of the S-rHCC group (P = 0.204). In patients treated with surgery only, OS and RFS were also comparable in the S-rHCC nrHCC group. Meanwhile, multivariate Cox regression analysis revealed that alpha-fetoprotein (AFP), alkaline phosphatase (ALP), and the main method of treatment were also prognostic factors for OS in patients with rHCC.
Ruptured HCC with a relatively small diameter (≤8 cm) can also achieve the same prognosis as nrHCC patients after aggressive treatment. It is also not recommended to include all patients with rHCC in stage T4.
根据TNM分期系统,破裂型肝细胞癌(rHCC)被归类为T4期,预后极差(未达预期),这一分类一直存在争议。本研究旨在评估不同肿瘤直径对BCLC 0/A期rHCC患者治疗后预后的具体影响。
收集2008年1月至2017年12月在本中心接受治疗的258例BCLC 0/A期HCC患者的数据,其中包括143例rHCC患者和115例非破裂型HCC(nrHCC)患者。借助X-tile软件,我们确定了rHCC患者肿瘤直径的临界值。以8 cm为临界值,将rHCC患者分为小rHCC组(n = 96)和大rHCC组(n = 47),采用Kaplan-Meier法比较小rHCC组和大rHCC组的预后,以及这两组与nrHCC组的预后,并使用多因素Cox风险模型筛选rHCC患者的预后因素。
小rHCC组的总生存期(OS)显著高于大rHCC组[风险比(HR)= 2.41(1.60 - 3.63)],nrHCC组的OS与小rHCC组相当(P = 0.204)。仅接受手术治疗的患者中,小rHCC组和nrHCC组的OS及无复发生存期(RFS)也相当。同时,多因素Cox回归分析显示,甲胎蛋白(AFP)、碱性磷酸酶(ALP)及主要治疗方法也是rHCC患者OS的预后因素。
直径相对较小(≤8 cm)的破裂型HCC患者在积极治疗后也可获得与nrHCC患者相同的预后。也不建议将所有rHCC患者都归为T4期。